Clinical Trial Update: Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib. [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of oral vorinostat combined with erlotinib in non-small cell lung cancer patients with EGFR mutations who progressed on erlotinib; the trial wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Erlotinib (Tarceva) (erlotinib)
• Vorinostat (Zolinza) (vorinostat)

Snippet

Sponsor: Spanish Lung Cancer Group | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-03-07